As U.S. virus numbers cool down, race against new strains heats up
Coronavirus deaths and cases per day in the U.S. dropped markedly over the last two weeks, but are still running at alarmingly high levels, and the effort to snuff out COVID19 is becoming an ever more urgent race between the vaccine and the mutating virus.
The government’s top infectious-disease expert, Dr. Anthony Fauci, said the improvement in numbers around the country appears to be the result of “natural peaking and then plateauing” after a holiday surge, rather than an effect of the rollout of vaccines that began in mid-December.
Deaths are running at an average of just under 3,100 a day, down from more than 3,350 less than two weeks ago. New cases are averaging about 170,000 a day after peaking at almost 250,000 on Jan. 11. The number of COVID-19 patients in the hospital in the U.S. has fallen to about 110,000 from a high of 132,000 on Jan. 7.
States that have been hot spots in recent weeks such as California and Arizona have shown similar improvements. On Monday, California lifted regional stay-at-home orders in favor of county-by-county restrictions and ended a 10 p.m. curfew.
Elsewhere, Minnesota school districts have begun bringing elementary students back for in-person learning. Chicago’s school system, the nation’s third-largest district, had hoped to bring teachers back Monday to prepare for students to return next month, but the teachers union has refused.
“I don’t think the dynamics of what we’re seeing now with the plateauing is significantly influenced yet — it will be soon — by the vaccine. I just think it’s the natural course of plateauing,” Fauci told NBC’s Today show.
Nationwide, about 18 million people, or less than 6% of the U.S. population, have received at least one dose of vaccine, including about 3 million who have gotten the second shot, according to the Centers for Disease Control and Prevention.
Only slightly more than half of the 41 million doses distributed to the states by the federal government have been injected into arms, by the CDC’s count.
Fauci also warned that the U.S. shouldn’t let its guard down as variants that are more contagious take hold.
The virus has killed over 419,000 Americans and caused more than 25 million confirmed infections in the United States. And health experts have warned that the variant sweeping through Britain will probably become the dominant source of infection in the U.S. by March. It has been reported in over 20 states so far. Another mutant version is circulating in South Africa.
“We don’t want to get complacent and think, ‘Oh, things are going in the right direction, we can pull back a bit,’” Fauci said.
To guard against the new variants, President Joe Biden planned to add South Africa to a list of more than two dozen countries under coronavirus-related travel restrictions, two White House officials said.
Non-U.S. travelers who have been to Brazil, Ireland, Britain and other European countries will be restricted from entering the U.S. under the rules being reimposed by Biden after President Donald Trump had moved to relax them, according to the officials, who spoke on condition of anonymity.
Fauci said scientists are already preparing to upgrade COVID-19 vaccines to address the mutated versions that erupted in Britain and South Africa.
He said there is “a very slight, modest diminution” of the effectiveness of COVID-19 vaccines against those variants, but “there’s enough cushion with the vaccines that we have that we still consider them to be effective” against both.
British authorities have said there is evidence that the variant circulating there may be more deadly than the original. Fauci called the South African variant even “more ominous,” noting that test tube studies suggest monoclonal antibodies do not work as well as a treatment against it.
Moderna, the maker of one of the two vaccines being used in the U.S., announced on Monday that it is beginning to test a possible booster dose against the South African version. Moderna CEO Stephane Bancel said the move was out of “an abundance of caution” after preliminary lab tests suggested its shot produced a weaker immune response to that variant.
The vaccine rollout in the U.S. has been marked by disarray and confusion, with states complaining in recent days about shortages and inadequate deliveries that have forced them to cancel mass vaccination events and tens of thousands of appointments.